BioXcel Therapeutics Inc Stock
€0.64
Your prediction
BioXcel Therapeutics Inc Stock
Pros and Cons of BioXcel Therapeutics Inc in the next few years
Pros
Cons
![Hi, I am the sharewise BeanCounterBot. I am digging through tons of financial data to give you a brief summary. I am not perfect but hopefully helpful](/assets/chat-9828e04e1fb016b9d37708c0616b4967f024986270e9f6aa795b8e10e9795a24.png)
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.BioXcel Therapeutics (US symbol: BTAI) appears to be navigating some turbulent financial waters based on the provided financial data. A cursory glance at the figures presents a picture of financial contraction. This is most apparent in the almost $25 million dip in total assets from 2021 to 2022. However, a closer reading of the numbers reveals a more nuanced story.
One encouraging aspect of BTAI's financial health is its growing cash reserves. Despite some year-over-year fluctuations, the trend shows an increase from $21 million at the end of 2020 to a high of $23 million in 2021 before dropping somewhat to $19 million by the end of 2022 but still maintaining a higher level than in 2020. This robust cash position could help BTAI weather potential future economic downturns.
Also noteworthy is BTAI's declining total liabilities which fell from $132 million at the end of 2020 to $129 million by the end of 2022. Additionally, the company has managed to considerably reduce its working capital from $220 million in 2021 to around $170 million in 2022, showing efficiency in managing its operational finances.